Novel endocrine therapy reduces the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...
News-Medical.Net on MSN

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Wistar scientists pinpoint a new approach to ovarian cancer treatment

Ovarian cancer tends to be resistant to hormone therapy, even when it should theoretically respond. Wistar Institute ...

How fasting may boost breast cancer treatment: New research reveals a key hormone link

New research reveals that intermittent fasting can significantly enhance the effectiveness of oestrogen-blocking breast ...
The Manila Times

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...
AOL

Testosterone drug comparison: Enclomiphene vs Anastrozole

Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) sometimes used to treat male secondary hypogonadism, or low testosterone caused by problems with the hypothalamus or ...
The Conversation

Puberty blockers: why politicians overriding doctors sets a dangerous precedent

Jaimie Veale was the founding President of the Professional Association for Transgender Health Aotearoa (PATHA). She is supported by a Rutherford Discovery Fellowship, awarded by Royal Society Te ...
U.S. News & World Report

Plasma Treatment Shows Promise For Menopause Symptoms Among Breast Cancer Survivors

Plasma Treatment Shows Promise For Menopause Symptoms Among Breast Cancer Survivors By Dennis Thompson HealthDay ReporterTHURSDAY, Nov. 20, 2025 (HealthDay News) — Plasma infusions may help breast ...